From January 21, 2025, Korea's Ministry of Food and Drug Safety (식약처, MFDS) prohibited the use of the word "exosome" in cosmetics advertising. The rule was a response to runaway marketing claims that had pushed exosome topical and injectable products into territory the agency considered medical, not cosmetic.
A year into enforcement, here is what the rule actually changed, what international patients should look for on Gangnam clinic menus in 2026, and why the regulatory direction matters.
What the rule says
- Cosmetic products and skincare brands cannot use "exosome" in advertising, packaging, or labeling.
- Cosmetic-use claims around tissue repair, regeneration, or hair growth using the term are also restricted.
- Systemic medicinal use of exosomes in Korea requires participation in authorized Phase 1b clinical trials — it is not a routine cosmetic offering.
- MFDS continues to regulate topical exosome boosters within a defined cosmetic framework, but the language around them has changed.
What clinics actually do now
Walk into a Gangnam dermatology clinic in 2026 and you will see:
- "Skin booster" menus that previously featured exosome lines now reframed under hyaluronic-acid, polynucleotide, or growth-factor categories.
- Hair-loss treatment menus that swapped explicit exosome language for "regenerative hair therapy" or "scalp booster" descriptions.
- Injectable products produced by KFDA/MFDS-permitted manufacturers continuing under their brand names rather than the umbrella term.
What this means for international patients
- Marketing language is more conservative — read it carefully. A clinic that still uses "exosome" prominently in 2026 marketing is either non-compliant or speaking about a clinical-trial context. Ask which.
- The product matters more than the term. Confirm which specific manufacturer's product is being injected and verify its MFDS status. Reputable clinics will provide the product name.
- Hair regeneration claims need especially careful reading. "Stem-cell hair therapy" and "exosome scalp treatment" cover a wide range of preparations, from well-studied to speculative.
- Don\'t conflate Korea\'s policy with FDA approval elsewhere. A product permitted in Korea may not be approved in the US or EU, and vice versa.
Why the rule was tightened
Three forces converged: (1) inconsistent product purity in early-market exosome cosmetics, (2) marketing claims that crossed into medical territory, and (3) cross-border concerns from international regulators about how Korean exosome marketing was being interpreted in third markets. The 2025 rule was a market-cleaning measure, not a ban on the underlying science.
Where the science actually stands
Exosome biology continues to be an active research area. Korean academic medical centers participate in clinical trials for hair, skin, and orthopedic indications. Current consensus:
- Topical exosome cosmetics: emerging evidence of skin-quality improvements; quality variability remains an issue.
- Injectable exosome therapies for routine cosmetic use: not a settled standard of care; outcomes vary with preparation.
- Regenerative medicine pipeline: Korea\'s regenerative market exceeded ₩1.2 trillion KRW in 2024, with continued growth projected through 2028.
How to ask in 2026
If a Gangnam clinic recommends an "advanced regenerative" treatment, ask:
- What is the specific product name and manufacturer?
- Is it MFDS-permitted, and in which category — cosmetic, medical device, or investigational?
- What evidence supports its use for my specific concern?
- What is the protocol, what are the alternatives, and what would happen if I declined?
The MFDS rule has matured the market more than it has shrunk it. The treatments are still on the menu — just under more honest names.